Article

“A Process-Based Approach to Conflicts of Interest”

2022-11-02

Abstract excerpt

The current system for disclosing financial conflicts of interest (COIs) can be traced back to the “Uniform requirements for manuscripts submitted to medical journals,” published in 1997. Meanwhile, new molecular and genetic therapies are transforming clinical medicine and these therapies have radically altered the financial landscape of drug development. The average price of new drugs has risen sharply, and in ni...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5c2d2638-f449-56e9-a4c4-26fea0f64b32
DOI: 10.22541/au.166740303.35406989/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

“A Process-Based Approach to Conflicts of Interest”DOI 10.22541/au.166740303.35406989/v1Read

Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory GuidelinesSemantic proximity Read

Ethical and human subject burdens of trials conducted to evaluate biosimilarsSemantic proximity Read

Challenges and Pathways in Regulating Next-Gen Biological TherapiesSemantic proximity Read

A few ethical issues in translational research for gene and cell therapySemantic proximity Read

Casimersen: First ApprovalSemantic proximity Read

Drug discovery and repurposing at Memorial Sloan Kettering Cancer Center: chemical biology drives translational medicine.Semantic proximity Read

Drug discovery and development in the age of molecular medicine.Semantic proximity Read

Conflicts of Interest in Medicine: From Individual Clinical Management to Population-Level GovernanceSemantic proximity Read

Optimizing regulatory frameworks for gene therapies in rare diseases: Challenges and solutionsSemantic proximity Read

Clinical development of gene- and cell-based therapies: overview of the European landscapeSemantic proximity Read

Comparison of Clinical Evidence Submitted to the FDA and EMA for Cell and Gene TherapiesSemantic proximity Read

Academic challenges on ATMPs’ development: a regulatory perspectiveSemantic proximity Read